Elevance Health stock heads into October 21 results with guidance

Published on 10/06/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock carries adjusted 2026 EPS guidance of at least USD 27, reaffirmed on September 10. Second-quarter adjusted EPS reached USD 7.45 versus USD 6.21 consensus, while 23 analysts set a USD 440.90 average target.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health stock (ISIN US0367521038) was trading at USD 396.53 on the NYSE on October 6, 2026 at 12:03 p.m. ET, up 0.51 percent from the prior close. The next company checkpoint is October 21, when Elevance Health will publish third-quarter 2026 results.

October 21 sets the next test

According to Elevance Health on October 5, 2026, the company will release its third-quarter results at 6:00 a.m. ET and hold its management call at 8:30 a.m. ET. The date matters because the latest quarter combined earnings strength with pressure in Medicaid and individual ACA operations.

Guidance stays above quarterly earnings

In its September 10, 2026 filing, the SEC filing said Elevance Health reaffirmed full-year 2026 adjusted earnings guidance of at least USD 27.00 per diluted share. The filing also reaffirmed a benefit expense ratio outlook of 90.2 percent plus or minus 50 basis points.

For the second quarter ended June 30, 2026, MarketBeat reported adjusted EPS of USD 7.45 versus USD 6.21 consensus and revenue of USD 49.83 billion versus USD 48.88 billion expected. Revenue increased 0.8 percent year over year, but prior-year EPS was USD 8.84, showing that the earnings comparison remains demanding despite the quarterly beat.

Consensus target tops the quote

MarketBeat's October 6, 2026 survey rates Elevance Health Moderate Buy, based on 23 analysts, including 15 Buy ratings and eight Holds. The average 12-month target is USD 440.90, with published targets from USD 393 to USD 488.

Against the NYSE price of USD 396.53 on October 6, 2026, the average target lies 11.2 percent above the price. That spread reflects a constructive consensus, while the wide target range points to differing views on medical-cost trends, Medicaid performance and the pace of improvement.

Stock stays below yearly high

Elevance Health stock remained 9.1 percent below its 52-week high of USD 436.24 on October 6, 2026, while the 52-week low stood at USD 274.84. The market capitalization was USD 86.0 billion and volume was 169,601 shares at the same intraday timestamp.